Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Nov;20(11):774-776.
doi: 10.1016/j.clml.2020.08.017. Epub 2020 Aug 22.

Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma

Hajime Yasuda  1 , Yutaka Tsukune  2 , Naoki Watanabe  2 , Kazuya Sugimoto  2 , Ayana Uchimura  2 , Misa Tateyama  3 , Yosuke Miyashita  3 , Yusuke Ochi  3 , Norio Komatsu  2
Affiliations
Case Reports

Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma

Hajime Yasuda et al. Clin Lymphoma Myeloma Leuk. 2020 Nov.
No abstract available

Keywords: Atypical presentation; CHOP; Coronavirus; Hematological malignancy; Obinutuzumab.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Transition of COVID-19 Pneumonia Lung Lesions in the Presented Case. Chest X-Rays and Computed Tomography Scans Show Constantly Migrating COVID-19 Lung Lesions. Days are Shown as the Number of Days After Hospitalization
See this image and copyright information in PMC

References

    1. Shah V., Ko Ko T., Zuckerman M., et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King’s College Hospital Experience. Br J Haematol. 2020 Jun 11 [Epub ahead of print] - PMC - PubMed
    1. Eisenberg R.A., Jawad A.F., Boyer J., et al. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol. 2013;33:388–396. - PMC - PubMed
    1. Nazi I., Kelton J.G., Larché M., et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013;122:1946–1953. - PMC - PubMed
    1. Gea-Banacloche J.C. Rituximab-associated infections. Semin Hematol. 2010;47:187–198. - PubMed
    1. Salles G., Seymour J.F., Offner F., et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42–51. - PubMed

Publication types

MeSH terms